Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bladder Cancer
New data from University of British Columbia illuminate research in bladder cancer
June 23rd, 2009
According to recent research from Victoria, Canada, "Intravesical Bacillus Calmette-Guerin (BCG) is widely used as an adjuvant therapy hi the treatment of superficial bladder cancer. BCG is administered as alive, attenuated form of Mycobacterium bovis, and acts as an immunomodulary agent to delay tumor progression." "BCG is generally well tolerated, though localized and systemic infectious complications may occur. A literature search revealed that tuberculous epididymitis is a rarely reported complication of intravesical BCG therapy, We report the case of an 82-year-old male who developed tuberculous epididymitis while undergoing intravesical BCG treatment for...
Source: Cancer Weekly (2009-06-23)
|
